Lv1
46 积分 2021-06-15 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
5天前
已完结
Safety update: EMA and FDA warn of liver problems with ▼fezolinetant
4个月前
已关闭
The use of Hormone Therapy after Surgery for Endometriosis: An Analysis
4个月前
已完结
Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis
4个月前
已完结
The 2022 hormone therapy position statement of The North American Menopause Society
5个月前
已完结
Guideline No. 447: Diagnosis and Management of Endometrial Polyps
5个月前
已完结
Guideline No. 461: The Management of Uterine Fibroids
5个月前
已完结
When MHT may be challenging: leiomyoma
5个月前
已完结
Management of Symptomatic Uterine Leiomyomas
5个月前
已完结
Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases
5个月前
已完结
皖公网安备34019202002308
